Prestige Consumer (PBH) Q1 2025 Earnings Report

In Q1 2025, Prestige Consumer Healthcare Inc (PBH) reported revenues of $267.1 million, reflecting a 4.4% decline from $279.3 million in the prior year. This drop was primarily due to supply chain constraints notably affecting their Clear Eyes product line. However, management expressed optimism about the overall performance, citing better-than-expected impacts from international growth, especially from the Hydralyte brand. The adjusted EPS stood at $0.90, down from $1.06 last year, yet reiterated a full-year EPS growth forecast of 5% to 6%. The company continues to demonstrate solid cash flow capabilities, with free cash flow reaching $54 million, enabling them to reduce debt and repurchase shares. Management remains committed to long-term growth despite facing near-term challenges.